Andere Sprachen Blueprint Medicines Corporation

Aktien

A14SDD

US09627Y1091

BPMC

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:26:46 10.06.2024			% 5 Tage	% 1. Jan.
101,5 ^USD	-1,82 %		-3,98 %	+9,14 %

07.06.	Insider von Blueprint Medicines verkaufte Aktien im Wert von $420.520, laut einer aktuellen SEC Einreichung	MT
05.06.	Blueprint Medicines Insider verkaufte Aktien im Wert von $259.263, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing	07.06.
Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing	05.06.
Blueprint Medicines Insider Sold Shares Worth $4,136,328, According to a Recent SEC Filing	04.06.
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)	31.05.
Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer	23.05.
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	23.05.
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	06.05.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.05.
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	03.05.
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	02.05.
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	02.05.
Blueprint Medicines: Q1 Earnings Snapshot	02.05.
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	02.05.
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	18.04.
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	11.04.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	22.03.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Blueprint Medicines Corporation

Aktien

A14SDD

US09627Y1091

BPMC

Andere Sprachen

Filter